MIRA vs. MBRX, AKTX, ABVC, MTEM, ELAB, ERNA, GHSI, AVTX, AEZS, and GRTX
Should you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Moleculin Biotech (MBRX), Akari Therapeutics (AKTX), ABVC BioPharma (ABVC), Molecular Templates (MTEM), Elevai Labs (ELAB), Eterna Therapeutics (ERNA), Guardion Health Sciences (GHSI), Avalo Therapeutics (AVTX), Aeterna Zentaris (AEZS), and Galera Therapeutics (GRTX). These companies are all part of the "pharmaceutical preparations" industry.
Moleculin Biotech (NASDAQ:MBRX) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment.
15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 6.7% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Moleculin Biotech's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.
Moleculin Biotech received 227 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users.
Moleculin Biotech presently has a consensus price target of $35.00, suggesting a potential upside of 654.31%. Given MIRA Pharmaceuticals' higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than MIRA Pharmaceuticals.
In the previous week, Moleculin Biotech had 8 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 10 mentions for Moleculin Biotech and 2 mentions for MIRA Pharmaceuticals. Moleculin Biotech's average media sentiment score of 1.89 beat MIRA Pharmaceuticals' score of 0.87 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.
Summary
Moleculin Biotech and MIRA Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.
Get MIRA Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MIRA Pharmaceuticals Competitors List
Related Companies and Tools
